Galvus
Novartis sues Biocon
April 4, 2014Sales and Marketing Biocon, Galvus, Gilead, Herceptin, Novartis, sofosbuvir
India’s status as a battleground for patent issues has been reinforced with the news that Novartis is suing Biocon over …
Lucentis approved in China
January 18, 2012Sales and Marketing China, Galvus, Lucentis, Novartis, em, emerging markets
Novartis’ eye treatment Lucentis has gained approval in China, and the firm has also launched its diabetes drug Galvus in …
Triple approval for Novartis in Japan
January 20, 2010Sales and Marketing Afinitor, Asia, Exforge, Galvus, Japan, Novartis, hypertension
Japanese regulators have approved three new Novartis medicines for use patients with type II diabetes, high blood pressure and advanced …
Surprise delay for Novartis’ Galvus
November 15, 2006Sales and Marketing Galvus, diabetes
The FDA will take three months longer than expected to review Novartis' new diabetes treatment, Galvus, after the pharma company …
Latest content
Five Facts about cardiovascular disease
August 9, 2026
